PSNL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. Despite a still-bullish longer-term moving-average structure and improving reimbursement-driven analyst optimism, PSNL is selling off (-5.12% today, -2.11% pre-market), trading below the pivot (10.19) and near first support (9.239). With no Intellectia buy signal today and near-term statistical bias pointing to weakness over the next week/month, the better call is to wait rather than chase a dip with elevated implied volatility ahead of the next earnings catalyst (2026-02-26).
Trend/structure: Bullish MA stack (SMA_5 > SMA_20 > SMA_200) suggests the broader trend remains constructive. Momentum: MACD histogram is positive (0.0905) but contracting, implying bullish momentum is fading rather than accelerating. RSI(6)=52.37 (neutral) provides no oversold bounce signal. Levels: Price 9.38 is below the pivot 10.19, with immediate support at S1=9.239 (very close); if that breaks, next support is S2=8.651. Resistance overhead at R1=11.141 then R2=11.729. Near-term pattern bias: Similar-pattern stats imply ~80% chance of a small uptick next day (+2.08%), but weakness over the next week (-2.5%) and month (-3.68%), which is not ideal for an impatient entry.
driven by reimbursement progress; Medicare coverage/reimbursement for NeXT Personal (breast cancer surveillance) remains the key commercial catalyst and de-risks parts of the clinical revenue outlook; potential event catalyst ahead with QDEC 2025 earnings on 2026-02-26 after hours (could reset expectations if revenue trajectory stabilizes).
which can cap upside until growth re-accelerates.
Latest reported quarter: 2025/Q3. Revenue fell to $14.495M (-43.62% YoY). Net income was -$21.652M (loss widened vs prior year by -44.61% YoY as stated). EPS was -$0.24 (down -62.50% YoY). Gross margin declined to 13.2% (-61.20% YoY). Overall: the quarter shows meaningful contraction and margin pressure—fundamentals are currently a headwind even if reimbursement wins improve the forward narrative.
Recent trend is improving/constructive: multiple firms raised price targets following reimbursement-related developments and Q3 performance (H.C. Wainwright up to $13; Lake Street up to $11; Morgan Stanley raised to $9 but remains Equal Weight; Guggenheim most recently lifted to $13 and reiterates Buy). Wall Street pros: reimbursement progress, clearer path to clinical revenue growth, and de-risking of the story. Cons: macro headwinds in biopharma demand (noted with lowered guidance previously) and the need to prove revenue re-acceleration and better margins. Trading flows: Hedge funds neutral; insiders neutral. Politicians/congress: no recent congress trading data available.
